AMRN is the official Nasdaq stock ticker symbol for Amarin Corporation plc, a specialized commercial-stage biopharmaceutical enterprise focused on developing and marketing novel treatments for cardiovascular diseases. The company's primary commercial asset is Vascepa (icosapent ethyl), a prescription drug indicated for reducing cardiovascular risks and managing severe hypertriglyceridemia. Investors, analysts, and traders track AMRN to evaluate performance metrics within the pharmaceutical and biotechnology equity sectors.